Registry-listed formulations

dorzolamide · mesh:C062765

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

8 source entries across 8 studies. This list may not include all unresolved or historical entries.

dorzolamide (drug)Registry intervention
Linked study entry; product equivalence not established
View study and source
DorzolamideRegistry intervention
Molecular identity unconfirmed
View study and source
Dorzolamide 2%Registry intervention
Molecular identity unconfirmed
View study and source
2% dorzolamideRegistry intervention
Molecular identity unconfirmed
View study and source
Dorzolamide 2 % eye drops solutionRegistry intervention
Linked study entry; product equivalence not established
View study and source
Dorzolamide 2%Registry intervention
Linked study entry; product equivalence not established
View study and source
[B]Registry intervention
Linked study entry; product equivalence not established
View study and source
DORZOLAMIDERegistry product
Molecular identity unconfirmed
Formulation reported by source: EYE DROPS, SOLUTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source

Success Metrics

Clinical Success Rate

75.0%

Based on 8 completed trials

Completion Rate

89%(8/9)

Active Trials

0(0%)

Results Posted

38%(3 trials)

Terminated

1(10%)

Phase Distribution

Not Applicable

30%

Phase 1

10%

Phase 2/3

10%

Phase 2

10%

Phase 3

20%

Phase 4

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Phase 1Safety & dosage

1(10.0%)

Phase 2Efficacy & side effects

1(10.0%)

Phase 2/3Combined phases

1(10.0%)

Phase 3Large-scale testing

2(20.0%)

Phase 4Post-market surveillance

2(20.0%)

N/ANon-phased studies

3(30.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(8)

Terminated(2)

Detailed Status

Completed8

Terminated1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (10.0%)

Phase 21 (10.0%)

Phase 2/31 (10.0%)

Phase 32 (20.0%)

Phase 42 (20.0%)

N/A3 (30.0%)

Trials by Status

completed880%

terminated110%

withdrawn110%

Recent Activity

0 active trials

Showing 5 of 10

terminatedphase_3

Clinical Trials (10)

Showing 10 of 10 trials

NCT02390284Phase 3

Stop Retinal Ganglion Cell Dysfunction Study

Terminated

NCT00572936Phase 2

Circadian Rhythms of Aqueous Humor Dynamics in Humans

Completed

NCT00716586Phase 4

Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration

Completed

NCT02967614Phase 1

KJ-TFC-004 Drug-drug Interaction Study

Completed

NCT02522039Not Applicable

Pupillary Response After Glaucoma Medication

Completed

NCT00275756Not Applicable

Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans

Withdrawn

NCT00619034Not Applicable

Pharmacological Intervention in Diabetic Retinopathy

Completed

NCT00878917Phase 3

Equivalence Study of Dorzolamide 2% Eye Drops Solution

Completed

NCT00991822Phase 2/3

A Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma

Completed

NCT00675207Phase 4

Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs